Insulet price target raised to $172 from $165 at Citi
Citi raised the firm's price target on Insulet to $172 from $165 and keeps a Neutral rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks that may be positioned for a catch-up trade, the analyst tells investors in a preview.